trending Market Intelligence /marketintelligence/en/news-insights/trending/c863tjzo98jpth-vnhpf2a2 content esgSubNav
In This List

Arcus Biosciences plans $100M IPO

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Arcus Biosciences plans $100M IPO

Arcus Biosciences Inc. plans to offer up to $100 million of its common shares in an IPO.

The clinical-stage biopharmaceutical company focused on creating cancer immunotherapies has applied to list its common stock on the New York Stock Exchange under the symbol RCUS.

Arcus plans to use the net proceeds to fund the clinical development of its product candidates, drug discovery and optimization programs as well as other general corporate purposes.

Citigroup Global Markets Inc., Goldman Sachs & Co. LLC and Leerink Partners LLC are acting as joint book-running managers of the offering.